- Home
- XERS
as 07-26-2024 4:00pm EST
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 321.7M | IPO Year: | 2018 |
| Target Price: | $4.63 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.46 - $3.26 | Next Earning Date: | 08-08-2024 |
| Revenue: | $171,356,000 | Revenue Growth: | 41.18% |
| Revenue Growth (this year): | 15.12% | Revenue Growth (next year): | 19.11% |
Stock Insider Trading Activity of Xeris Biopharma Holdings Inc. (XERS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Schmid John P. | XERS | Director | May 10 '24 | Buy | $1.91 | 5,400 | $10,314.00 | 16,400 | SEC Form 4 |
| Schmid John P. | XERS | Director | Mar 14 '24 | Buy | $2.16 | 4,500 | $9,720.00 | 11,000 | SEC Form 4 |
| SHERMAN JEFFREY W | XERS | Director | Nov 27 '23 | Buy | $1.87 | 5,400 | $10,098.00 | 5,400 | SEC Form 4 |
| HALKUFF DAWN | XERS | Director | Nov 20 '23 | Buy | $1.84 | 5,410 | $9,954.40 | 5,410 | SEC Form 4 |
| Pieper Steven | XERS | See Remarks | Nov 20 '23 | Buy | $1.95 | 28,000 | $54,600.00 | 1,176,912 | SEC Form 4 |
| Shannon John Patrick Jr | XERS | See Remarks | Nov 17 '23 | Buy | $1.64 | 30,769 | $50,399.62 | 1,408,575 | SEC Form 4 |
| Schmid John P. | XERS | Director | Nov 16 '23 | Buy | $1.51 | 6,500 | $9,815.00 | 6,500 | SEC Form 4 |
| PERSKY MARLA | XERS | Director | Nov 14 '23 | Buy | $1.58 | 6,370 | $10,057.59 | 6,370 | SEC Form 4 |
Latest Xeris Biopharma Holdings Inc. News
XERS Breaking Stock News: Dive into XERS Ticker-Specific Updates for Smart Investing
Business Wire
2 days ago
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
Zacks
2 days ago
Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
MT Newswires
19 days ago
Xeris Biopharma Appoints John Shannon as CEO
Business Wire
19 days ago
Xeris Biopharma Announces CEO Succession Plan
Business Wire
23 days ago
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
Business Wire
2 months ago
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
MT Newswires
2 months ago
Sector Update: Health Care Stocks Higher in Afternoon Trading
Compare XERS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XERS Xeris Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.